Structure via PubChem · Public domain (PubChem)
mazindol
Sign in to saveAlso known as Mazanor®, Sanorex®, Mazindolo, Mazindolum
Mazindol, sold under the brand names Mazanor and Sanorex, is an appetite suppressant which is used in the short-term treatment of obesity. It is also used off-label in the treatment of narcolepsy and cataplexy. The drug is taken orally.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 462100725
- Drug.image
- Mazindol.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 175px
- Drug.tradename
- Mazanor, Sanorex
- Drug.routes_of_administration
- Oral
- Drug.class
- Serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI); Appetite stimulant; Wakefulness-promoting agent; Stimulant
- Drug.ATC_prefix
- A08
- Drug.ATC_suffix
- AA05
- Drug.legal_AU
- S4
- Drug.legal_BR
- B2
- Drug.legal_CA
- Schedule IV
- Drug.legal_US
- Schedule IV
- Drug.legal_DE
- Anlage II
- Drug.bioavailability
- 93%
- Drug.metabolism
- Hepatic
- Drug.elimination_half life
- 10–13 hours
via Wikipedia infobox
Chemical data
- Formula
- C16H13ClN2O
- Molecular weight
- 284.74 g/mol
- IUPAC name
- 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
- SMILES
- C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
- InChIKey
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N
- XLogP
- 2.2
- Polar surface area
- 35.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1973
- Admin. routes
- oral
- Indications
- obesity, attention deficit hyperactivity disorder, cocaine dependence, narcolepsy-cataplexy syndrome
via ChEMBL · EBI
Research
939 papers- [Mazindol].Nihon rinsho. Japanese journal of clinical medicine · 2011
- Mazindol: a risk factor for pulmonary arterial hypertension?Sleep medicine · 2017
- Clinical studies with mazindol.Obesity research · 1995
- Mazindol.The Medical letter on drugs and therapeutics · 1982
- Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.The American journal of clinical nutrition · 1992
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 284.072
- Has use
- medication
Show 8 more facts
- chemical formula
- C₁₆H₁₃ClN₂O
- medical condition treated
- obesity
- canonical SMILES
- C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
- Commons category
- Mazindol
- defined daily dose
- 1
- subject has role
- stimulant
- MCN code
- 2933.91.51
- physically interacts with
- solute carrier family 6 member 3
Sources (6)
via Wikidata · CC0
~5 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Overdose
- Pharmacology
- Pharmacodynamics
- Chemistry
- Tautomers
- Synthesis
- Related compounds
- Research
- Attention deficit hyperactivity disorder
- References
Mazindol, sold under the brand names Mazanor and Sanorex, is an appetite suppressant which is used in the short-term treatment of obesity. It is also used off-label in the treatment of narcolepsy and cataplexy. The drug is taken orally.
Mazindol was developed by Sandoz-Wander in the 1960s. The US Food and Drug Administration approved mazindol in June 1973, but Novartis, the manufacturer, discontinued it in 1999 for reasons unrelated to its efficacy or safety.
Excerpted from Wikipedia’s “mazindol” article, available under the CC BY-SA 4.0 licence.